Halozyme Therapeutics HALO
$91.35 −$1.69 (-1.82%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $91.35 0.00%
Open$93.64
Prev close$93.04
Day range$90.79 – $93.64
Volume1.50M
Market cap$10.41B
P/E (TTM)22.8
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$492.97M+39.2% YoY
Operating profit$294.97M+35.4% YoY
Net profit$247.05M+41.0% YoY
Diluted EPS$2.01+40.6% YoY
Free cash flow$255.22M+45.4% YoY
Operating cash flow$258.27M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin82.3%
Operating margin55.9%
Net margin26.9%
Return on equity216.4%
Return on assets17.0%
Return on invested capital19.3%
Current ratio3.88
Liabilities / assets101.6%
Cash & investments$1.07B
Total debt$3.25B
Net cash (debt)-$2.18B
Free cash flow / sales33.2%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $492.97M | $481.00M | $376.71M | $1.40B | $451.77M |
| Total Operating Revenue | $492.97M | $481.00M | $376.71M | $1.40B | $451.77M |
| Cost of Revenue | $82.48M | $79.17M | $79.24M | $228.77M | $78.77M |
| Gross Profit | $410.50M | $401.83M | $297.47M | $1.17B | $373.00M |
| Operating Expense | $115.53M | $114.17M | $112.95M | $365.24M | $132.30M |
| Selling and Admin Expenses | $58.24M | $57.00M | $57.88M | $207.09M | $77.03M |
| Research & Development | $27.78M | $27.66M | $25.56M | $81.49M | $31.90M |
| Depreciation & Amortization & Depletion | $29.51M | $29.51M | $29.51M | $76.66M | $23.38M |
| -Depreciation & Amortization | $29.51M | $29.51M | $29.51M | $76.66M | $23.38M |
| Operating Profit | $294.97M | $287.65M | $184.52M | $802.59M | $240.70M |
| Net Non-Operating Interest Income (Expense) | -$6.05M | -$5.59M | -$5.51M | -$18.13M | -$4.91M |
| Non-Operating Interest Expense | $6.05M | $5.59M | $5.51M | $18.13M | $4.91M |
| Other Income (Expense) | $1.71M | $2.84M | $1.32M | -$317.59M | -$336.63M |
| Gain on Sale of Security | $2.17M | $2.84M | $1.32M | $21.47M | $2.43M |
| Special Income (Charges) | -$465,000.00 | – | – | -$339.06M | -$339.06M |
| -Less:Other Special Charges | $465,000.00 | – | – | $5.48M | – |
| Pretax Profit | $290.63M | $284.90M | $180.33M | $466.88M | -$100.85M |
| Tax | $43.58M | $54.99M | $30.28M | $149.99M | $40.74M |
| Net Profit | $247.05M | $229.91M | $150.05M | $316.89M | -$141.59M |
| Profit from Continuing Operations | $247.05M | $229.91M | $150.05M | $316.89M | -$141.59M |
| Net Income to Parent Company | $247.05M | $229.91M | $150.05M | $316.89M | -$141.59M |
| Net Income to Common Stockholders | $247.05M | $229.91M | $150.05M | $316.89M | -$141.59M |
| Basic EPS | $2.17 | $1.96 | $1.27 | $2.64 | -$1.20 |
| Diluted EPS | $2.01 | $1.90 | $1.22 | $2.56 | -$1.20 |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | $284.89M | – |
| -Less:Impairment of Capital Assets | – | – | – | $48.70M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $3.47B | $2.58B | $2.67B | $2.53B | $2.53B |
| Total Current Assets | $1.85B | $933.02M | $1.00B | $825.21M | $825.21M |
| Cash and Cash Equivalents & Short-Term Investments | $1.07B | $231.00M | $318.62M | $142.82M | $142.82M |
| -Cash and Cash Equivalents | $1.03B | $163.14M | $309.75M | $133.82M | $133.82M |
| -Short Term Investments | $44.40M | $67.87M | $8.87M | $9.00M | $9.00M |
| Receivables | $525.59M | $455.83M | $457.99M | $441.27M | $441.27M |
| -Accounts Receivable | $529.51M | $461.99M | $468.25M | $434.27M | $434.27M |
| -Other Receivables | $7.00M | $2.50M | – | $16.61M | $16.61M |
| -Receivables Adjustments Allowances | -$10.92M | -$8.66M | -$10.26M | -$9.61M | -$9.61M |
| Inventory | $132.61M | $137.14M | $155.47M | $176.48M | $176.48M |
| Other Current Assets | $114.14M | $109.06M | $70.96M | $64.64M | $64.64M |
| Total Non-Current Assets | $1.63B | $1.64B | $1.67B | $1.70B | $1.70B |
| Net PPE | $82.29M | $84.27M | $82.23M | $82.14M | $82.14M |
| -Gross PPE | $118.24M | $118.21M | $117.45M | $115.30M | $115.30M |
| -Accumulated Depreciation | -$35.95M | -$33.94M | -$35.22M | -$33.16M | -$33.16M |
| Goodwill and Other Intangible Assets | $1.47B | $1.50B | $1.53B | $1.56B | $1.56B |
| -Goodwill | $581.73M | $581.73M | $582.32M | $580.36M | $580.36M |
| -Other Intangible Assets | $892.93M | $922.44M | $951.96M | $981.47M | $981.47M |
| Other Non-Current Assets | $69.67M | $55.94M | $53.18M | $56.15M | $56.15M |
| Total Liabilities | $3.53B | $2.43B | $2.45B | $2.48B | $2.48B |
| Total Current Liabilities | $476.09M | $344.44M | $363.21M | $177.09M | $177.09M |
| Payables | $33.55M | $23.61M | $14.10M | $20.90M | $20.90M |
| -Accounts Payable | $33.55M | $23.61M | $14.10M | $20.90M | $20.90M |
| Current Accrued Expenses | $136.93M | $111.86M | $140.37M | $156.19M | $156.19M |
| Short-Term Debt and Capital Lease Obligation | $305.61M | $208.97M | $208.74M | – | – |
| -Current Debt | $305.61M | $208.97M | $208.74M | – | – |
| Total Non-Current Liabilities | $3.05B | $2.09B | $2.09B | $2.30B | $2.30B |
| Long Term Debt and Capital Lease Obligation | $2.94B | $1.94B | $1.94B | $2.14B | $2.14B |
| -Long Term Debt | $2.94B | $1.94B | $1.94B | $2.14B | $2.14B |
| Non-Current Deferred Liabilities | $6.34M | $49.06M | $47.53M | $42.92M | $42.92M |
| Other Non-Current Liabilities | $101.47M | $102.68M | $106.45M | $113.86M | $113.86M |
| Total Equity | -$55.24M | $143.54M | $219.64M | $48.81M | $48.81M |
| Stockholders' Equity | -$55.24M | $143.54M | $219.64M | $48.81M | $48.81M |
| Capital Stock | $114,000.00 | $114,000.00 | $118,000.00 | $118,000.00 | $118,000.00 |
| -Common Stock | $114,000.00 | $114,000.00 | $118,000.00 | $118,000.00 | $118,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $0.00 | $0.00 | $27.39M | $12.00M | $12.00M |
| Retained Earnings | -$58.13M | $151.26M | $204.84M | $54.79M | $54.79M |
| Gains/Losses Not Affecting Retained Earnings | $2.78M | -$7.83M | -$12.70M | -$18.09M | -$18.09M |
| Non-Current Deferred Assets | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $258.27M | $240.89M | $180.08M | $651.56M | $219.03M |
| Net cash flow from continuing operations | $258.27M | $240.89M | $180.08M | $651.56M | $219.03M |
| Net Income from Continuing Operations | $247.05M | $229.91M | $150.05M | $316.89M | -$141.59M |
| Gain/Loss from Continuing Operations | $0.00 | – | – | $2.45M | $2.38M |
| Depreciation & Depletion & Amortization | $34.20M | $33.97M | $33.73M | $88.05M | $26.68M |
| Deferred Tax | -$5.15M | $907,000.00 | $3.43M | $634,000.00 | -$16.77M |
| Other Non-Cash Items | $2.95M | $2.47M | $2.46M | $298.82M | $292.59M |
| Change in Working Capital | -$37.03M | -$43.57M | -$26.20M | -$152.26M | -$9.43M |
| -Change in Receivables | -$69.77M | $2.16M | -$19.55M | -$128.06M | -$90.48M |
| -Change in Inventory | $5.04M | $18.33M | $27.38M | $2.55M | $18.78M |
| -Change in Prepaid Assets | -$13.21M | -$41.15M | -$9.11M | -$32.96M | $28.42M |
| -Change in Payables and Accrued Expense | $40.90M | -$22.91M | -$24.92M | $6.21M | $33.85M |
| Net cash flow from investing | $20.95M | -$62.66M | -$2.88M | -$545.81M | -$741.79M |
| Net Cash Flow from Continuing Investing Activities | $20.95M | -$62.66M | -$2.88M | -$545.81M | -$741.79M |
| Net PPE Purchase and Sale | -$3.05M | -$4.17M | -$3.74M | -$6.97M | -$1.43M |
| Net Business Purchase and Sale | $0.00 | $0.00 | $710,000.00 | -$725.97M | -$725.97M |
| Net Investment Purchase and Sale | $24.00M | -$58.49M | $154,000.00 | $474.89M | $273.38M |
| Financing Cash Flow | $587.65M | -$326.25M | -$1.61M | -$85.17M | $239.52M |
| Net Cash Flow from Continuing Financing Activities | $587.65M | -$326.25M | -$1.61M | -$85.17M | $239.52M |
| Net Common Stock Issuance | -$67.27M | – | – | -$342.37M | $0.00 |
| Proceeds from Stock Option Exercised | $22.80M | $6.48M | -$1.61M | $21.83M | $4.15M |
| Ending Cash Balance | $1.03B | $163.99M | $312.01M | $136.42M | $136.42M |
| Net Change in Cash | $866.86M | -$148.02M | $175.59M | $20.57M | -$283.24M |
| Beginning Cash Balance | $163.99M | $312.01M | $136.42M | $115.85M | $419.67M |
| Free Cash Flow | $255.22M | $236.72M | $176.34M | $356.82M | -$70.17M |
| Net Intangibles Purchase and Sale | – | – | – | -$287.77M | – |
| Net Issuance Payments Of Debt | – | – | – | $451.13M | $451.13M |
| Net Other Financing Charges | – | – | – | -$215.76M | – |
No comments yet — be the first to weigh in on HALO.
Sign in to join the discussion.